BIOSIGHT logo .png
Biosight Receives Orphan Medicinal Product Designation from the European Medicines Agency for Aspacytarabine (BST-236) for the Treatment of Acute Myeloid Leukemia
December 17, 2020 08:00 ET | BioSight Ltd.
AIRPORT CITY, Israel, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
BIOSIGHT logo .png
Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
December 07, 2020 08:00 ET | BioSight Ltd.
Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival Durable responses achieved as monotherapy with...
BIOSIGHT logo .png
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
December 02, 2020 08:00 ET | BioSight Ltd.
AIRPORT CITY, Israel, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
BIOSIGHT logo .png
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
November 05, 2020 10:15 ET | BioSight Ltd.
AIRPORT CITY, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
BIOSIGHT logo .png
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
August 04, 2020 08:00 ET | BioSight Ltd.
AIRPORT CITY, Israel, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
BIOSIGHT logo .png
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies
July 21, 2020 08:30 ET | BioSight Ltd.
AIRPORT CITY, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
BIOSIGHT logo .png
Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference
May 26, 2020 08:30 ET | BioSight Ltd.
AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
BIOSIGHT logo .png
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.
May 18, 2020 09:00 ET | BioSight Ltd.
AIRPORT CITY, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
BIOSIGHT logo .png
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
March 11, 2020 09:44 ET | BioSight Ltd.
AIRPORT CITY, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...